Determination of intracellular sulphydryl compounds by microchip electrophoresis with selective chemiluminescence detection

An analytical method based on microchip electrophoresis (MCE) and chemiluminescence detection (CL) was developed for the determination of intracellular sulphydryl compounds. Cell injection/loading, cytolysis, electrophoretic separation, and CL detection were integrated onto a simple cross-microfluid...

Full description

Saved in:
Bibliographic Details
Published inJournal of Chromatography A Vol. 1217; no. 36; pp. 5732 - 5736
Main Authors Zhao, Shulin, Huang, Yong, Ye, Fanggui, Shi, Ming, Liu, Yi-Ming
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 03.09.2010
Amsterdam; New York: Elsevier
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:An analytical method based on microchip electrophoresis (MCE) and chemiluminescence detection (CL) was developed for the determination of intracellular sulphydryl compounds. Cell injection/loading, cytolysis, electrophoretic separation, and CL detection were integrated onto a simple cross-microfluidic chip. Selective CL detection of sulphydryl compounds was achieved by deploying the luminol–Na 2S 2O 8 reaction. Under the CL conditions selected, many endogenous compounds in biological systems such as amino acids, biogenic amines, peptides and proteins did not produce any CL signal, which further ensured a high selectivity of the proposed MCE–CL assays. Sulphydryl compounds including cysteine (Cys), glutathione (GSH), and hemoglobin (Hb) were selected as the test compounds. The MCE separation was completed within 120 s. The detection limits were estimated to be 7 amol for Cys, 32 amol for GSH and 69 amol for Hb, respectively. The present method was applied to analyze individual red blood cells collected from both healthy subjects and cancer patients. It was found that the average intracellular contents of Cys, GSH and Hb were in the ranges of 26–43 amol/cell, 128–323 amol/cell and 522–667 amol/cell, respectively for cancer patients, compared to 579–609 amol Hb/cell and not detectable Cys and GSH for healthy subjects.
Bibliography:http://dx.doi.org/10.1016/j.chroma.2010.07.012
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-9673
1873-3778
DOI:10.1016/j.chroma.2010.07.012